Todos Medical Enters into Joint Venture Agreement
Post# of 30028
(Total Views: 651)
Posted On: 12/03/2018 8:35:23 AM
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
BY GlobeNewswire
— 8:30 AM ET 12/03/2018
REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF Loading...) , a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. ( AMBS Loading...) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease. LymPro Test is an immune-based neurodiagnostic blood test originally developed at Leipzig University in Germany.
Image: slogo.jpg
“We are extremely pleased to be entering into this JV Agreement surrounding LymPro Test 2.0, which is positioned as potentially the first diagnostic blood test for Alzheimer’s disease,” said Herman Weiss, MD MBA, CEO of Todos Medical ( TOMDF Loading...). “With LymPro’s focus on measuring immune markers that are directly linked to well established cell proliferation processes, we are expanding our understanding of how the body’s immune system responds to disease and how we can use this response to diagnose early and monitor the progression of Alzheimer’s disease. We believe this could be an invaluable tool for pharmaceutical companies’ development of novel treatments for Alzheimer’s, as well as a critical component to early diagnosis that may have a meaningful impact on the cost-curve associated with Alzheimer’s, estimated to be currently $250 billion annually in the US, and expected to grow to $1.2 trillion by 2050.” The closing of this JV Agreement is subject to Todos Medical ( TOMDF Loading...) raising $1,000,000 from institutional investors.
“Todos Medical has robust data sets and patent portfolios for the early detection of cancer,” said Gerald E. Commissiong, President & CEO of Amarantus. “With regulatory approval in Europe and niche markets in Asia, Todos Medical ( TOMDF Loading...) is preparing to commercialize its diagnostics markers, which is a key value inflection for any diagnostic company. LymPro will help Todos Medical ( TOMDF Loading...) build upon its deep understanding of the interplay between immune system and aberrant cell proliferation processes that lead to disease. We believe this combination will help drive the clinical and commercial plan for LymPro and deliver significant shareholder value for Amarantus.”
Under the terms of the JV Agreement, Todos Medical ( TOMDF Loading...) will issue to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical ( TOMDF Loading...) stock, in exchange for 19.99% of a newly- formed entity called Breakthrough Diagnostics, Inc., with an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos’ shares outstanding. All rights to LymPro and certain other diagnostic assets will be assigned to Breakthrough Diagnostics, as part of the transaction. Todos Medical's ( TOMDF Loading...) exclusive option will be exercisable upon Amarantus entering into an amended and restated license agreement with the University of Leipzig.
About Todos Medical Ltd. ( TOMDF Loading...)
Todos Medical Ltd. ( TOMDF Loading...) an Israeli company headquartered in Rehovot, Israel, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.
For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.
About the LymPro Test
The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
https://globenewswire.com/news-release/2018/1...t-2-0.html
ALOHA
BY GlobeNewswire
— 8:30 AM ET 12/03/2018
REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF Loading...) , a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. ( AMBS Loading...) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease. LymPro Test is an immune-based neurodiagnostic blood test originally developed at Leipzig University in Germany.
Image: slogo.jpg
“We are extremely pleased to be entering into this JV Agreement surrounding LymPro Test 2.0, which is positioned as potentially the first diagnostic blood test for Alzheimer’s disease,” said Herman Weiss, MD MBA, CEO of Todos Medical ( TOMDF Loading...). “With LymPro’s focus on measuring immune markers that are directly linked to well established cell proliferation processes, we are expanding our understanding of how the body’s immune system responds to disease and how we can use this response to diagnose early and monitor the progression of Alzheimer’s disease. We believe this could be an invaluable tool for pharmaceutical companies’ development of novel treatments for Alzheimer’s, as well as a critical component to early diagnosis that may have a meaningful impact on the cost-curve associated with Alzheimer’s, estimated to be currently $250 billion annually in the US, and expected to grow to $1.2 trillion by 2050.” The closing of this JV Agreement is subject to Todos Medical ( TOMDF Loading...) raising $1,000,000 from institutional investors.
“Todos Medical has robust data sets and patent portfolios for the early detection of cancer,” said Gerald E. Commissiong, President & CEO of Amarantus. “With regulatory approval in Europe and niche markets in Asia, Todos Medical ( TOMDF Loading...) is preparing to commercialize its diagnostics markers, which is a key value inflection for any diagnostic company. LymPro will help Todos Medical ( TOMDF Loading...) build upon its deep understanding of the interplay between immune system and aberrant cell proliferation processes that lead to disease. We believe this combination will help drive the clinical and commercial plan for LymPro and deliver significant shareholder value for Amarantus.”
Under the terms of the JV Agreement, Todos Medical ( TOMDF Loading...) will issue to Amarantus 19.99% of the outstanding ordinary shares of Todos Medical ( TOMDF Loading...) stock, in exchange for 19.99% of a newly- formed entity called Breakthrough Diagnostics, Inc., with an exclusive option to acquire the remaining 80.01% of Breakthrough Diagnostics in exchange for an additional 30.01% of Todos’ shares outstanding. All rights to LymPro and certain other diagnostic assets will be assigned to Breakthrough Diagnostics, as part of the transaction. Todos Medical's ( TOMDF Loading...) exclusive option will be exercisable upon Amarantus entering into an amended and restated license agreement with the University of Leipzig.
About Todos Medical Ltd. ( TOMDF Loading...)
Todos Medical Ltd. ( TOMDF Loading...) an Israeli company headquartered in Rehovot, Israel, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.
For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.
About the LymPro Test
The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
https://globenewswire.com/news-release/2018/1...t-2-0.html
ALOHA
(9)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼